White Glo Crave Away toothpaste, which claims to "help suppress appetite and reduce food cravings" and whiten teeth, is expected to hit U.S. shelves by Aug. 1, Great White Trading Company announces April 17. An Herbal Whitening Toothpaste and Professional Choice Toothpaste also will be available under the brand in the U.S. this summer. According to the Santa Rosa, Calif.-based marketer, White Glo oral care products, which are developed by the Australian firm Barros Laboratories, are ranked third in market share in Australia and "are destined to be a recognized U.S. brand." Crave Away's homeopathic formula includes Nux Vomica 30X, which is "well known to help reduce cravings and the desire to over indulge by sending a signal to the brain indicating fullness," the firm states. The product also contains Fucus Vesiculosus 6X and Garcinia Quaesita 5X, an ingredient containing hydroxyl-citric acid (HCA) which may "help to control appetite and reduce the desire for carbohydrates," Great White adds. The SRP for a 5.2 oz tube is $5.99-$6.49...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Too many “uninformative” drug trials fail to justify the excessively high prices of many medicines, while there is too much evidentiary uncertainty in European pricing and reimbursement systems, warned Anja Schiel from Norway’s NOMA.
It appears that the European Medicines Agency is making progress on its re-examination of Eli Lilly’s Alzheimer’s disease drug Kisunla, following an initial rejection in March based on safety concerns.
Health Canada’s proposal to no longer require biosimilar manufacturers to prove the safety and efficacy of their product through Phase III clinical trials marks a pivotal change in Canada’s regulatory approach.
